238 Shares in ResMed Inc. (NYSE:RMD) Purchased by Rosenberg Matthew Hamilton

Rosenberg Matthew Hamilton bought a new stake in shares of ResMed Inc. (NYSE:RMD) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 238 shares of the medical equipment provider’s stock, valued at approximately $54,000.

A number of other large investors also recently made changes to their positions in RMD. True Wealth Design LLC boosted its holdings in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of ResMed during the 3rd quarter valued at $34,000. Capital Performance Advisors LLP purchased a new position in shares of ResMed during the 3rd quarter valued at $60,000. Quest Partners LLC increased its stake in shares of ResMed by 44.1% in the second quarter. Quest Partners LLC now owns 327 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 100 shares during the last quarter. Finally, Quarry LP increased its stake in shares of ResMed by 271.9% in the second quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 242 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Price Performance

NYSE RMD opened at $228.61 on Wednesday. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 1 year low of $168.29 and a 1 year high of $260.49. The company has a fifty day simple moving average of $239.24 and a 200 day simple moving average of $232.06. The company has a market cap of $33.56 billion, a P/E ratio of 30.28, a P/E/G ratio of 1.73 and a beta of 0.70.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.64 earnings per share. On average, sell-side analysts predict that ResMed Inc. will post 9.34 EPS for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th were issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend was Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is presently 28.08%.

Analyst Upgrades and Downgrades

RMD has been the subject of a number of research reports. Robert W. Baird lifted their price objective on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Wolfe Research reiterated an “underperform” rating and set a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. Baird R W upgraded ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. Royal Bank of Canada raised their price objective on shares of ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research report on Friday, October 25th. Finally, StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ResMed has a consensus rating of “Hold” and an average target price of $233.09.

Insiders Place Their Bets

In related news, Director Witte Jan De sold 796 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the sale, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $248.74, for a total value of $497,480.00. Following the transaction, the director now owns 83,204 shares in the company, valued at $20,696,162.96. This represents a 2.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,099 shares of company stock worth $2,719,385 in the last ninety days. Insiders own 0.71% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.